Search

Displaying results 7501 - 7510 of 7655 in total
  1. Drug

    Semaxanib

    go.drugbank.com/drugs/DB06436
    Investigational

  2. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial...

  3. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy. This study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral cont...

  4. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

  5. Drug

    TRU-015

    go.drugbank.com/drugs/DB05580
    Investigational

  6. Drug

    CRD5

    go.drugbank.com/drugs/DB05587
    Experimental

  7. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth a...

  8. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it ...

  9. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform

  10. Drug

    Diethylnorspermine

    go.drugbank.com/drugs/DB06445
    Investigational